Objective: To assess whether there is an association between improvement of computed tomography imaging results prior to interval debulking with survival in patients treated by neoadjuvant chemotherapy.
INTRODUCTION
Ovarian cancer is the leading cause of death from gyne co logic malignancies [1] . A retrospective study by Griffiths [2] in 1975 demonstrated a strong association between post operative largest residual tumor and survival. Since then, initial cytoreductive (debulking) surgery and adjuvant chemother apy has become the standard of care in advanced epithelial ovarian cancer [35] .
Currently the treatment concept of neoadjuvant chemo therapy has been introduced. In this alternative management approach the initial treatment in some advanced ovarian car cinoma patients usually consists of 3 courses of chemo therapy followed by cytoreductive surgery (interval debulking) and
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Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? 184 www.ejgo.org additional three courses of postoperative chemotherapy. Pro posed advantages of neoadjuvant chemotherapy include an increased rate of optimal residual disease, less extensive sur gery, reduced blood loss, lower morbidity, shortened hospital stay and improved quality of life.
Neoadjuvant chemotherapy may also act as a mechanism to select out patients with platinumresistant disease. While still controversial, it has been found in many retrospective and prospective studies that the outcome after the neoadjuvant approach is not inferior to that after initial cytoreductive sur gery [69] .
Various noninvasive means have been proposed to predict cytoreduction inability for the selection of patients in whom the neodjuvant approach is more appropriate. These include various computed tomography (CT) criteria [1012] clinical and CA125 level criteria [13, 14] . A few investigations deal with the ability to predict progression free survival (PFS) and overall survival prior to interval debul king [15 18 ]. Most of them are by assessment of CA125 level reduction [1517] . Up to now no reliable prediction method has been found.
The purpose of the present study was to assess whether there is an association between improvement of CT imaging results prior to interval debulking with survival in patients treated by neoadjuvant chemotherapy.
MATERIALS AND METHODS
The records of all advanced ovarian, primary peritoneal and tubal carcinoma patients who after diagnosis had initial che motherapy during the period 20002010, were abstracted after institutional review board approval. The diagnosis of ma lignancy in these patients was confirmed by cytology exami nation of ascitic fluid and/or by core biopsy. Patients were al located to neoadjuvant chemotherapy according to Nelson's CT criteria [10] i.e., mainly in the presence of ex ten sive disease in the upper abdomen and/or disease outside the peritoneal cavity. Their clinical and outcome data were recorded. Neoad juvant and postinterval debulking chemotherapy consisted of intravenous paclitaxel (175 mg/m 2 ) and carboplatin (AUC 6) for three 21day cycles.
Results of CT imaging at diagnosis and prior to interval debulking were interpreted and compared by a certified roentgenologist (IU) who was unaware of the outcome. Two pa rameters where assessed: the change of the dia meter and number of abnormal findings, especially in the areas consid ered to be nondebulkable, and the change in the amount of ascites. Evaluation of response was based on RECIST criteria [19] . In brief according to RECIST criteria complete response (CR) is defined as disappearance of all target lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) is when there is neither sufficient shrinkage to qualify for PR nor suf ficient increase to qualify for progressive disease.
In the present study the assessed variables were scored on a 02 scale based (but not identical) on the RECIST criteria where 0 represented no improvement (SD according to RECIST), 1 represented some improvement (PR according to RECIST), and 2 represented marked improvement i.e., a reduction of more than 50% in the number and/or the size of the CT findings and no or only minimal presence of ascitic fluid (less stringent than CR according to RECIST). In addition the CA125 level at diagnosis and its level prior to interval debulking were recorded. A CA125 decrease to <35 U/mL was considered as normalization. The percent reduc tion of CA125 levels from the value at diagnosis to the value prior of interval debulking was also calculated. An assessment of PFS, i.e., the time between the last course of post interval debulking chemotherapy and the time of recurrence, and an assessment of survival was made according to the change in CT imaging results, according to CA125 normalization and according to the percent reduction of CA125 levels. PFS and overall survival were assessed by the KaplanMeier method and differences by the logrank test. Patients with recurrence were treated by a large number [47] and dissimilar treatment lines and by a variety of chemotherapeutic agents.
RESULTS
Initial chemotherapy was given to 48 patients. Of the total group 11 patients did not undergo interval debulking 2 ex pired prior to surgery of concurrent diseases, 3 refused surgery and 6 had progressive disease. The study group thus compris es 37 consecutive patients (29 with ovarian carcinoma, 6 with primary peritoneal carcinoma and 2 with tubal carcinoma) who were managed by the neoadjuvant approach and under went interval debulking. All tumors were of the papillary se rous type. The mean age of the patients was 64.1±10.6 years (range, 38 to 81 years). Additional selected characteristics of the patients are presented in Table 1 . The largest percentage of patients was in the 6069 age group. The majority of the pa tients presented with abdominal pain and/or distention, and had stage IIIC grade 3 tumors. More than half of the patients had no visible macroscopic disease after interval debulking surgery and more than half where defined as platinum sensi tive i.e. recurrence occurred more than 6 months after the end www.ejgo.org 185 of primary treatment. When compared to the CT at diagnosis, the CT prior to in terval debulking showed no demonstrable improvement, some improvement and marked improvement in 2 (5.4%), 16 (43.2%) and 19 (51.4%) patients, respectively. Since there were only 2 patients with no improvement, they were combined with those with some improvement for the purpose of further analysis. No ascites was present at diagnosis in 7 patients. In all the remaining 30 study group patients a marked improve ment in the amount of ascites was observed. Normalization of CA125 was found in 16 (43.2%) and a reduction greater than 90% was found in 24 (64.9%) of the patients. A decrease of more than 50% of CA125 levels was observed in all pa tients. The PFS according to improvement of CT findings is presented in Fig. 1 . The median PFS of the study group was 7.9 months. The PFS of the patients with no/some improvement and of those with marked improvement was 7.93 and 7.23 respectively (p=0.89; 95% CI, 0.55 to 1.99). The median survival of the patients was 49.2 months (mean, 36.9±23.8 months). The median survival of those with no/some improvement and of those with marked improvement was 45.8 months and 52.5 months respectively (p=0.95; 95% CI, 0.41 to 2.09). Table 2 presents the association of CA125 response with PFS and with survival. No statistically significant difference was found between the different categories of CA125 response.
DISCUSSION
To the best of our knowledge the association between the improvement of imaging findings prior to interval debulking surgery with survival has not been reported until now. We found that the median PFS of patients with marked im provement in the size and number of abnormal findings was similar to those with less favorable imaging results, and that marked improvement in the amount of ascites was present in *The percent reduction of CA125 levels from the value at diagnosis to the value prior of interval debulking. 186 www.ejgo.org all patients. Our study therefore indicates that imaging results prior to interval debulking surgery cannot be used for predic tion of PFS. This holds true for survival as well. However, we feel that it is less relevant because of the heterogeneous man agement of the patients subsequent to recurrence. It is noteworthy that the PFS of our patients is of shorter duration and that the median survival is longer compared to those reported by Vergote et al. [9] (7.9 vs. 12 months and 49.2 vs. 30 months, respectively). The differences can be attributed to our small number of patients. Although the patients were informed after 3 treatment cycles that the chance of response to additional treatment is slim, they all requested and received multiple additional treatment cycles. Whether the longer sur vival of our patients is due to the administration of the large number (up to 7) of treatment lines, is questionable. Indeed recent evidence suggests that more number of cycles does not improve the outcome [20] .
The rate of patients in our series with no residual disease after interval debulking (62%) is in the range of that reported by Vergote et al. [9] and Brun et al. [21] (50% and 73%, respec tively).
Only four previous studies attempted to compare variables at diagnosis with the same variables after neoadjuvant che motherapy and prior to interval debulking surgery in order to investigate whether improvement in these variables might predict outcome. In two studies Le et al. reported that normal ization, defined as a reduction in serum CA125 levels to less than 35 U/mL, in 16 patients with elevated levels at diagnosis [15] and that a decrease of at least 50% from baseline prior to interval debulking surgery [16] were found not to be indepen dent predictors of either progressionfree or overall survival. In contrast, in a third study, CA125 regression coefficient was calculated and found to be a significant prognostic factor for overall survival [17] . This study was criticized [15] because the definition of the response using a CA125 regression coef ficient was not a standard one and difficult to reproduce, and because in the majority of patients significant cytoreductive surgery was not attempted. In an additional study, in vitro tumor cloning assay results regarding platinum or paclitaxel resistance of 22 ovarian cancer patients treated with neoadju vant chemotherapy were assessed and were also found not to be predictive of PFS [18] . The results of our study, namely the lack of association of PFS and survival with CA125 normaliza tion and with the percent CA125 reduction, are in line with those reported by Le et al. [15, 16] .
The ability to predict the outcome after neoadjuvant chemo therapy prior to interval debulking is important for two main reasons. It is of great prognostic significance and it may iden tify patients who might have an unfavorable prognosis thus allowing a more rational planning of further management. This could include additional treatment with different chemo therapeutic agents prior or after interval debulking or to forgo, after informed consent, interval debulking with its inherent morbidity.
It seems that neither improvement in imaging results nor CA125 level response can predict the outcome after neoadju vant chemotherapy prior to interval debulking. We are aware of the small size of our series (post hock power of only about 10%), and that our results should be confirmed in a larger study. Whether a larger series would yield a different result re mains to be proven. Since positron emission tomography (PET) is an indicator of the metabolic state of malignancies it is pos sible that PETCT could be a more accurate imaging modality to predict the outcome prior to interval debulking. However, this remains to be investigated. Further studies are indicated in order to find a method that will enable prediction of outcome after neoadjuvant chemo therapy and prior to interval debulking.
